These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1514 related items for PubMed ID: 31318152

  • 1. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA.
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
    MacIsaac RJ, Thomas MC.
    Clin J Am Soc Nephrol; 2018 Feb 07; 13(2):321-323. PubMed ID: 29321176
    [No Abstract] [Full Text] [Related]

  • 9. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X, Divino V, Amamoo J, Xie L, Coyle KB, Gamble CL, Guevarra M, Paprocki Y, King AA.
    Clin Drug Investig; 2024 Apr 07; 44(4):271-284. PubMed ID: 38507188
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, Azushima K, Urate S, Suzuki T, Abe E, Wakui H, Tamura K.
    Cardiovasc Diabetol; 2021 Jan 07; 20(1):14. PubMed ID: 33413348
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Kintzoglanakis K, Diamantis C, Mariolis A, Paschou SA.
    Diab Vasc Dis Res; 2024 Jan 07; 21(4):14791641241269743. PubMed ID: 39139128
    [Abstract] [Full Text] [Related]

  • 19. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
    Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R.
    J Am Heart Assoc; 2021 Jul 06; 10(13):e021084. PubMed ID: 33998258
    [Abstract] [Full Text] [Related]

  • 20. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
    Hiramatsu T, Ito H, Okumura S, Asano Y, Iguchi D, Furuta S.
    Diab Vasc Dis Res; 2020 Jul 06; 17(6):1479164120971220. PubMed ID: 33371732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.